SEC Filings

AVEXIS, INC. filed this Form 424B5 on 06/19/2017
Entire Document

Table of Contents


          This prospectus supplement, the accompanying prospectus, the documents incorporated by reference herein and therein and any related free writing prospectus contain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions intended to identify statements about the future. These statements speak only as of the date of this prospectus supplement and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward looking statements include, without limitation, statements about the following:

    the timing, progress and results of preclinical studies and clinical trials for AVXS-101 and any other product candidates, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;

    the timing of and our ability to obtain and maintain regulatory approval of AVXS-101;

    the proposed clinical development pathway for AVXS-101, including the expected trial design for our proposed pivotal clinical trials, and the acceptability of the results of such trials for regulatory approval of AVXS-101 by the FDA or comparable foreign regulatory authorities;

    the proposed timing of filing investigational new drug applications with the U.S. Food and Drug Administration in connection with gene therapies we are developing for ALS and Rett syndrome in connection with the recent licenses executed with REGENXBIO Inc.;

    our expectations regarding timing for meetings with regulatory agencies;

    our expectations regarding the size of the patient populations for our product candidates, if approved for commercial use;

    our manufacturing capabilities and strategy, including the scalability and commercial viability of our manufacturing methods and processes and our ability to establish a satisfactory potency assay for AVXS-101;

    our ability to successfully commercialize AVXS-101;

    our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing;

    our ability to identify and develop new product candidates, including our planned new programs in Rett syndrome and ALS;

    our ability to identify, recruit and retain key personnel;

    our and our licensors' ability to protect and enforce our intellectual property protection for AVXS-101, and the scope of such protection;

    our financial performance;

    the development of and projections relating to our competitors or our industry;


© AveXis, Inc. All Rights Reserved.